Ivenia ABUS Premium was designed to help streamline the supplemental breast ultrasound workloads and enhance diagnoses by improving ease of use and image reproducibility.
There are no standards requiring radiologists to report on the presence of BACs, even though up to half of referring providers have indicated they would prefer to be made aware of the finding.
Breast artery calcifications are already visible when radiologists review mammograms, but nothing typically happens with them. Researchers aimed to see if AI could help translate those findings into an easy-to-understand cardiovascular risk score.
New technology now being considered by the FDA for approval can capture coronary inflammation on CCTA images and provide risk assessments. What could this mean for the future of cardiac care? We spoke to one researcher to learn more.
Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.
The algorithm has an edge over standard black box-style artificial intelligence applications because providers are able to see how it reaches conclusions.
Breast artery calcifications are already visible when radiologists review mammograms, but nothing typically happens with them. Researchers aimed to see if AI could help translate those findings into an easy-to-understand cardiovascular risk score.
Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.
The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.
